Compare ARXS & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARXS | MEDP |
|---|---|---|
| Founded | N/A | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1B | 15.4B |
| IPO Year | 2026 | 2016 |
| Metric | ARXS | MEDP |
|---|---|---|
| Price | $58.40 | $575.53 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $473.17 |
| AVG Volume (30 Days) | ★ 787.7K | 375.8K |
| Earning Date | N/A | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.98 |
| EPS | N/A | ★ 8.53 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.19 |
| Revenue Next Year | N/A | $7.75 |
| P/E Ratio | ★ N/A | $67.21 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.69 | $373.00 |
| 52 Week High | $58.39 | $677.90 |
| Indicator | ARXS | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 72.31 | N/A |
| Support Level | $40.79 | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 3.25 | 0.00 |
| MACD | 1.65 | 0.00 |
| Stochastic Oscillator | 90.96 | 0.00 |
Arxis Inc designs and manufactures proprietary electronic and mechanical components used in applications that require performance in extreme environments. The company operates in two reportable segments: i) Electronic Components: It provides specialized, engineered electronic components and interconnect solutions, including connectors, cable assemblies, microelectronic packaging, RF and microwave products, power products, sensors, capacitors and resistors. and ii) Mechanical Components: It provides precision and self-lubricating bearings, seals, springs, gaskets and ducting, and radar absorbing materials. The majority of the company's revenue is derived from the Mechanical Components segment. Geographically, it generates the maximum revenue from the United States.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.